Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

BioCentury | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

BioCentury | Aug 4, 2017
Company News

Shire evaluating neurology pipeline

BioCentury | Aug 3, 2017
Company News

Shire evaluating neurology pipeline

BioCentury | Apr 20, 2017
Clinical News

Vyvanse regulatory update

BioCentury | Aug 24, 2015
Clinical News

Vyvanse: Phase III data

BioCentury | Sep 29, 2014
Clinical News

Vyvanse regulatory update

BioCentury | Sep 15, 2014
Clinical News

Vyvanse: Phase IV data

BioCentury | Sep 15, 2014
Clinical News

Vyvanse: Phase IV data

Items per page:
1 - 10 of 22